HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business & Finance In Brief: GSK | MJN | Actavis | ScripsAmerica

This article was originally published in The Tan Sheet

Executive Summary

GSK spotlights oral care; Mead Johnson weighs China pricing effects; USANA builds on Asia enthusiasm; FMC lands omega-3 firm Epax; Actavis eyes additional M&A activity; ScripsAmerica grows OTC and Rx distribution.

You may also be interested in...



ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways

ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.

Only Alli Remains After Glaxo’s OTC Transaction With Aspen

GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.

IGBA Appoints Frittelli As 2022 Chair

The IGBA has appointed Vivian Frittelli as chair of the organization for 2022, taking over from Sudarshan Jain. It is Frittelli’s second time as chair of IGBA, having taken up the mantle the first time following its 2015 rebrand.

Topics

Related Companies

UsernamePublicRestriction

Register

RS124406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel